BACE2 Antibody

Blue Ice

Predicted: 57 kDa
Observed: 57 kDa

BACE2 Antibody: Accumulation of the amyloid-beta (Abeta) plaque in the cerebral cortex is a critical event in the pathogenesis of Alzheimer's disease. Abeta peptide is generated by proteolytic cleavage of the beta-amyloid protein precursor (APP) at beta- and gamma-sites by proteases. The long-sought beta-secretase was recently identified by several groups independently and designated beta-site APP cleaving enzyme (BACE) and aspartyl protease 2 (Asp2). BACE/Asp2 is a novel transmembrane aspartic protease and co-localizes with APP. A BACE homolog was recently cloned and designated BACE2, Asp1, DRAP (for Down region aspartic protease), and memapsin 1. BACE2 also cleaves APP at b-site and at a different site within Abeta. BACE2 locates on chromosome 21q22.3, the so-called ‘Down critical region', suggesting that BACE2 and Abeta may also contribute to the pathogenesis of Down syndrome.

Trial Size

6561812

PRS-1301-0.1mg

1 mg/ml

BACE2 antibody can be used for detection of BACE2 by Western blot at 1 μ g/mL. Antibody can also be used for immunohistochemistry starting at 2 μ g/mL.
Antibody validated: Western Blot in human samples and Immunohistochemistry in rat samples. All other applications and species not yet tested.

BACE2 antibody was raised against a peptide corresponding to amino acids near the carboxy terminus of human BACE2.

The immunogen is located within the last 50 amino acids of BACE2.

beta-site APP-cleaving enzyme 2

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.